New yellow fever vaccine shows promise in japanese adults

NCT ID NCT07222059

Completed ⭐️ VACCINE ⭐️ Sponsor: Sanofi Pasteur, a Sanofi Company Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a yellow fever vaccine in 254 healthy adults aged 18 and older in Japan. Participants received one shot under the skin and were followed for about a month. The goal was to see if the vaccine triggers a strong immune response and is safe.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: yellow fever vaccine (live)
What this could lead to: If successful, this could confirm that the vaccine is safe and effective for adults, supporting its use in Japan.
What could go wrong: This is a single-arm, open-label study with no comparison group, so results may not be definitive. The vaccine is already established elsewhere, so the upside is limited.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for YELLOW FEVER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

yellow fever prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

YELLOW FEVER

Contacts and locations

Locations

Investigational Site Number : 3920001

Takatsuki, Osaka, 569-1192, Japan
Investigational Site Number : 3920002

Chūō, Tokyo, 103-0025, Japan
Investigational Site Number : 3920003

Shinjuku-ku, Tokyo, 169-0072, Japan
Investigational Site Number : 3920004

Taitō City, Tokyo, 111-0036, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.